Table 1.
CPE rank | Participants prescribed % | |
---|---|---|
Truvada® (emtricitabine and tenofovir) | 3, 1 | 64 |
Norvir® ritonavir | 1 | 48 |
Reyataz® atazanavir | 2 | 44 |
Kaletra lopinavir + ritonavir | 3 | 40 |
Epzicom® abacavir + lamivudine | 3, 2 | 32 |
Viread® tenofovir | 1 | 12 |
Prezista® darunavir | 3 | 12 |
Isentress® raltegravir | 3 | 12 |
Lexiva® fosamprenavir | 3 | 8 |
Epivir® lamivudine | 2 | 4 |
Combivir® lamivudine + zidovudine | 4, 2 | 4 |
Intelence® etravirine | 2 | 4 |
Retrovir® zidovudine | 4 | 4 |
Trizivir® abacavir + lamivudine + zidovudine | 3 | 4 |
Medications with CNS Penetration mean 7.8 (±2.2)